Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Lundgren

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Pediatric Diabetes|April 30, 2025
Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 DiabetesTaylor M Triolo, Laura M Jacobsen, David Cuthbertson, et al.
Diabetes Care|August 7, 2021
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet CohortsMichael G Voss, David D Cuthbertson, Mario M Cleves, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2024
Early Appearance of Thyroid Autoimmunity in Children Followed From Birth for Type 1 Diabetes RiskBerglind Jonsdottir, Joanna L Clasen, Kendra Vehik, et al.
Diabetes Care|January 19, 2022
Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY StudyLaura M Jacobsen, Kendra Vehik, Riitta Veijola, et al.
Pediatric Diabetes|November 2, 2022
The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT-studyJanne Houben, Martha Janssens, Christiane Winkler, et al.
BMJ Open|November 10, 2021
Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocolAnette-Gabriele Ziegler, Stefanie Arnolds, Annika Kölln, et al.
Diabetologia|February 14, 2024
Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available dataPedro F Teixeira, Tadej Battelino, Anneli Carlsson, et al.
Contemporary Clinical Trials Communications|February 7, 2025
Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocolSandra Hummel, Alexandra Käßl, Stefanie Arnolds, et al.
BMJ Paediatrics Open|January 12, 2024
Vitamin D insufficiency in infants with increased risk of developing type 1 diabetes: a secondary analysis of the POInT StudyAn Jacobs, Maarten Warnants, Veronika Vollmuth, et al.
Infection|June 14, 2024
Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemicIvo Zeller, Andreas Weiss, Stefanie Arnolds, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Pediatric Diabetes|April 30, 2025
Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 DiabetesTaylor M Triolo, Laura M Jacobsen, David Cuthbertson, et al.
Diabetes Care|August 7, 2021
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet CohortsMichael G Voss, David D Cuthbertson, Mario M Cleves, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2024
Early Appearance of Thyroid Autoimmunity in Children Followed From Birth for Type 1 Diabetes RiskBerglind Jonsdottir, Joanna L Clasen, Kendra Vehik, et al.
Diabetes Care|January 19, 2022
Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY StudyLaura M Jacobsen, Kendra Vehik, Riitta Veijola, et al.
Pediatric Diabetes|November 2, 2022
The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT-studyJanne Houben, Martha Janssens, Christiane Winkler, et al.
BMJ Open|November 10, 2021
Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocolAnette-Gabriele Ziegler, Stefanie Arnolds, Annika Kölln, et al.
Diabetologia|February 14, 2024
Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available dataPedro F Teixeira, Tadej Battelino, Anneli Carlsson, et al.
Contemporary Clinical Trials Communications|February 7, 2025
Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocolSandra Hummel, Alexandra Käßl, Stefanie Arnolds, et al.
BMJ Paediatrics Open|January 12, 2024
Vitamin D insufficiency in infants with increased risk of developing type 1 diabetes: a secondary analysis of the POInT StudyAn Jacobs, Maarten Warnants, Veronika Vollmuth, et al.
Infection|June 14, 2024
Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemicIvo Zeller, Andreas Weiss, Stefanie Arnolds, et al.
Pageof 7